Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of intermittent and continuous aerosol nebulization by limiting condensate management; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is based in Exeter, New Hampshire.
IPO Year: 2018
Exchange: NYSE
Website: vapotherm.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/6/2022 | $12.00 → $5.00 | Buy → Hold | Canaccord Genuity |
| 4/7/2022 | $23.00 → $8.00 | Overweight → Underweight | Piper Sandler |
4/A - VAPOTHERM INC (0001253176) (Issuer)
Canaccord Genuity downgraded Vapotherm from Buy to Hold and set a new price target of $5.00 from $12.00 previously
Piper Sandler downgraded Vapotherm from Overweight to Underweight and set a new price target of $8.00 from $23.00 previously
Piper Sandler reiterated coverage of Vapotherm with a rating of Overweight and set a new price target of $36.00 from $39.00 previously
4 - VAPOTHERM INC (0001253176) (Issuer)
4 - VAPOTHERM INC (0001253176) (Issuer)
4 - VAPOTHERM INC (0001253176) (Issuer)
4 - VAPOTHERM INC (0001253176) (Issuer)
4 - VAPOTHERM INC (0001253176) (Issuer)
4 - VAPOTHERM INC (0001253176) (Issuer)
4 - VAPOTHERM INC (0001253176) (Issuer)
4 - VAPOTHERM INC (0001253176) (Issuer)
4 - VAPOTHERM INC (0001253176) (Issuer)
4 - VAPOTHERM INC (0001253176) (Issuer)
SC 13D/A - VAPOTHERM INC (0001253176) (Subject)
SC 13D/A - VAPOTHERM INC (0001253176) (Subject)
SC 13G - VAPOTHERM INC (0001253176) (Subject)
SC 13D - VAPOTHERM INC (0001253176) (Subject)
SC 13D/A - VAPOTHERM INC (0001253176) (Subject)
SC 13G/A - VAPOTHERM INC (0001253176) (Subject)
SC 13G/A - VAPOTHERM INC (0001253176) (Subject)
SC 13G/A - VAPOTHERM INC (0001253176) (Subject)
SC 13G/A - VAPOTHERM INC (0001253176) (Subject)
SC 13G/A - VAPOTHERM INC (0001253176) (Subject)
15-12G - VAPOTHERM INC (0001253176) (Filer)
EFFECT - VAPOTHERM INC (0001253176) (Filer)
EFFECT - VAPOTHERM INC (0001253176) (Filer)
EFFECT - VAPOTHERM INC (0001253176) (Filer)
S-8 POS - VAPOTHERM INC (0001253176) (Filer)
S-8 POS - VAPOTHERM INC (0001253176) (Filer)
S-8 POS - VAPOTHERM INC (0001253176) (Filer)
S-8 POS - VAPOTHERM INC (0001253176) (Filer)
S-8 POS - VAPOTHERM INC (0001253176) (Filer)
S-8 POS - VAPOTHERM INC (0001253176) (Filer)
EXETER, N.H., Sept. 20, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has closed its merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC. On June 17, 2024, the Company announced that it had signed a definitive agreement and plan of merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive agreem
EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights. Second Quarter 2024 Financial Results and Related Highlights Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023Disposables revenue increased by 13.9% as compared to the second quarter of 2023U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023Gross margin in the second quarter of 2024 was 49.
EXETER, N.H., June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners ("SLR") have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50.0 million of new preferred equity capital into the b
EXETER, N.H., May 9, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2024 financial results and related highlights. First Quarter 2024 Financial Results and Related Highlights Net revenue for the first quarter of 2024 was $19.1 million, an increase of 7.9% as compared to the first quarter of 2023Disposables revenue increased by 13.5% as compared to the first quarter of 2023Gross margin in the first quarter of 2024 was 50.5% as compared to 35.0% in the first quarter of 2023For the first quarter of 2024, GAAP opera
Partnership enables Vapotherm to build a robust and secure solution 80% faster than the standard development timeline to meet data visualization and device management goals for HVT® 2.0 and future Home system SAN FRANCISCO, March 20, 2024 /PRNewswire/ -- Onymos, developer of the world's first Features-as-a-Service platform, and Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm"), a global medical technology company whose proprietary high-velocity therapy® products treat patients of all ages suffering from respiratory distress, today announced the formation of a development and commercialization partnership. This partnership will help Vapotherm create a unique respiratory digital platform to meet its
EXETER, N.H., March 15, 2024 /PRNewswire/ -- Vapotherm, Inc., (OTCQX:VAPO), ("Vapotherm" or the "Company") today announced the debut of its Access365™ Home Ventilation Solution at the upcoming MEDTRADE conference. Dr. Jessica Whittle, Chief Medical Officer of Vapotherm, emphasized the company's commitment to improving the lives of hypercapnic patients in the home. "Our mission is to improve quality of life and reduce hospital readmissions for patients who struggle with respiratory disease. Access365 will provide optimal treatment at home, especially for COPD patients, by combi
EXETER, N.H., March 6, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company") today announced that David Yamane, MD was awarded the Star Research Award by the Society for Critical Care Medicine (SCCM) at the 2024 Critical Care Congress. The award is in recognition of the HYPERACT study – a new multi-center, randomized controlled trial which offers high velocity therapy as an additional, more comfortable, option for clinicians treating acute exacerbations of moderate-severe COPD. (https://journals.lww.com/ccmjournal/citation/2024/01001/42__high_veloc
EXETER, N.H., Feb. 29, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, is pleased to announce the regulatory approval of the HVT 2.0 system in Brazil. The therapeutic respiratory devices market in Brazil, valued at USD 302.4 million in 2022, is anticipated to grow at a CAGR of 6.5% from 2023 to 2030.1 With approximately 8 million cases
EXETER, N.H., Feb. 22, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced fourth quarter and fiscal year 2023 financial results and related highlights. Fourth Quarter 2023 Financial Results and Related Highlights Net revenue for the fourth quarter of 2023 was $19.7 million, an increase of 5.7% as compared to the fourth quarter of 2022Disposables revenue increased by 10.4% as compared to the fourth quarter of 2022Gross margin in the fourth quarter of 2023 was 46.6% as compared to 27.5% in the fourth quarter of 2022 and 39.6% in th
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX:OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Vapotherm, Inc. (OTCQX:VAPO), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, has qualified to trade on the OTCQX® Best Market. Vapotherm, Inc. voluntarily transferred to OTCQX from the New York Stock Exchange. Vapotherm, Inc. begins trading today on OTCQX under the symbol "VAPO." U.S. investors can find current financial disclosure and Real-Time Level 2 quot
Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors
Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper
Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v
Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced fourth quarter and fiscal year 2022 financial results. Fourth Quarter 2022 Summary Total revenue for the fourth quarter of 2022 was $18.7 million Gross margin was 27.5% in the fourth quarter of 2022 Substantially completed move of manufacturing operations from New Hampshire to Mexico Fiscal Year 2022 Summary Total revenue for 2022 was $66.8 million Launched next generation High Velocity Therapy platform, HVT 2.0 Cost structure has been streamlined which resulted in a decrease in non-GAAP cash operating expenses from $100.8 million in 2021 to $83.6 million in 2022 Worldwide installed base of High Ve
Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced preliminary unaudited fourth quarter and full year 2022 net results. Preliminary Fourth Quarter and Full Year 2022 Financial Results For the fourth quarter of 2022, the Company expects net revenue to be in the range of $18.4 million to $18.7 million. For the fourth quarter of 2022, the Company expects gross margin to be in the range of 27% to 28%. For the fourth quarter of 2022, the Com
Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced third quarter 2022 financial results. Third Quarter 2022 Summary Total revenue for the third quarter of 2022 was $13.5 million, an increase of 4.4% over the second quarter of 2022 U.S. disposables revenue of $9.5 million reflects a 19.6% increase over U.S. disposables revenue of $7.9 million in the second quarter of 2022 Cost structure has been streamlined which will result in a decrease in Non-GAAP cash operating expenses from $100 million in 2021 to $60 million to $62 million in 2023 Move of manufacturing operations from New Hampshire to Mexico is on track "Our revenue increased sequentially from the s
Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the third quarter of 2022 after the close of trading on Wednesday, November 2, 2022. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789
Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2022 financial results. Second Quarter 2022 Summary Total revenue for the second quarter of 2022 was $13.0 million, a decrease of 37.1% over the second quarter of 2021 Disposables revenue for the second quarter of 2022 was $7.9 million, a decrease of 38.2% over the second quarter of 2021 Worldwide installed base of Precision Flow systems increased by approximately 400 units in the second quarter of 2022 to over 36,100 "The second quarter of 2022 was a tough quarter for us due to low respiratory patient census and Customer destocking of inventory purchased during the Omicron wave in the first
Vapotherm, Inc. (NYSE:VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products which are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Wednesday, August 3, 2022. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial (888) 330-2391 for U.S. callers, or +1 (240) 789-2702
Revenue of $21.6 Million In-Line with Preliminary Revenue of $20.5 Million to $21.5 Million Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2022 financial results. First Quarter 2022 Summary Total revenue for the first quarter of 2022 was $21.6 million, a decrease of 33.1% over the first quarter of 2021 Disposables revenue for the first quarter of 2022 was $14.9 million, a decrease of 13.3% over the first quarter of 2021 Worldwide installed base of Precision Flow systems increased by over 500 units in the first quarter of 2022 to over 35,700 "The first quarter of 2022 was challenging as respiratory patient census was low for both seasonal
TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b
SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t